Towards Clinical Trials for ISRIB

ISRIB has for some years been under investigation as a way to reduce the impact of neurodegeneration and improve cognitive function. It is one of a number of small molecule approaches to upregulate forms of cellular housekeeping, the unfolded protein response in this case. More cellular maintenance in principle means a lower burden of molecular damage and cellular dysfunction at any given time. Since most of these maintenance processes appear to decline in efficacy with age, improvement is a compensatory strategy that might help. In many cases exercise produces more impressive effects than the present state of the art in pharmacology, however. We shall see how ISRIB does in humans, but the mouse data is interesting.

ISRIB has restored memory formation in mice months after traumatic brain injuries and shown potential in treating neurodegenerative diseases, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS). It also seems to reduce age-related cognitive decline. Researchers believe that the reason the molecule can do so much is that it plays an essential role in how the brain handles stress from physical injuries or neurological diseases. Under siege from such problems, the brain, in essence, shuts down cognitive functions like memory formation to protect itself. The new molecule reverses that.

Will ISRIB work to reverse cognitive decline in people? We still don't know. So far most of the work has been done in mice or human cells in a petri dish. But we will soon know more: in 2015 the molecule was licensed by Calico Labs, the Silicon Valley biotech established by the founders of Google to find drugs based on the biology of aging. It aims to transform the molecule into a treatment for a wide array of disorders, including ALS and Parkinson's disease, as well as the damage from traumatic brain injury. In 2021, Calico announced that human safety trials had begun on the first drug candidate for neurodegenerative diseases it had developed based on ISRIB, and that a study in ALS patients was slated to begin later in the year.



hi my mother in bad shape dementia. interested in isrib's.. time is of the essance. thankyou.

Posted by: frank kopas at April 7th, 2022 1:50 PM

Tell Joe Biden to use Operation warp speed and get this drug developed fast and to perfection. And Mix it in a cocktail with the dimentia drug that just came out! If a mouse can be saved than for sure a human! I would pay $8000 for it!

Posted by: Jano Kamciyan at April 10th, 2022 2:38 AM

This research seems very promising.

Posted by: Susan Saleem at May 11th, 2022 9:40 AM

How do I get to be part of the clinical trials for humans? Contact me please.

Posted by: Richard Eichmann at June 25th, 2022 2:41 PM

The last I heard Google had taken over the study of this drug from UC San Francisco. It looks like the studies have progressed. Is this true? If so it could be the finding of the century for so many suffering from cognitive decline, Alzheimer's, brain damage, Down's Syndrome and so much more.

Thank you,

Posted by: Frances at August 17th, 2022 7:46 PM
Comment Submission

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.